FFA
CHRS icon

Farther Finance Advisors’s Coherus Oncology CHRS Stock Holding History

Farther Finance Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.71K Buy
2,135
+123
+6% +$218 ﹤0.01% 4637
2025
Q4 		$2.86K Buy
+2,012
New +$2.93K ﹤0.01% 4554
2025
Q2 		– Sell
-47
Closed -$38 – 4530
2025
Q1 		$38 Hold
47
– – ﹤0.01% 4148
2024
Q4 		$65 Buy
+47
New +$53 ﹤0.01% 3845
2024
Q2 		– Sell
-91
Closed -$218 – 3839
2024
Q1 		$218 Buy
91
+88
+2,933% +$217 ﹤0.01% 3251
2023
Q4 		$10 Buy
+3
New +$8 ﹤0.01% 3500

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return